Hemophilia

Myelodysplastic Syndrome (MDS) & Chronic myelomonocytic leukemia (CMML)

HIGHER RISK MDS/CMML

- Naive to Hypomethylating Agents
  - HEMMDS0041: Phase III Azacitidine w or w/o MBG453 for Patients with Intermediate, High or Very High Risk MDS or CMML-2
    - PI: Greenberg
    - Pending
    - Priority 3
  - HEMMDS0039: Phase III Magrolimab in Combo w/ Azacitidine vs Azacitidine +Placebo in Treatment-Naive HighRisk MDS
    - PI: Greenberg Forty Seven
    - Priority 2
  - HEMMDS0037: Phase III APR-246 + Azacitidine vs Azacitidine Alone in TP53 Mutant Myelodysplastic Syndromes
    - PI: Greenberg Aprea Therapeutics
    - Priority 4

- Naive to Hypomethylating Agents with TP53 mutation
  - HEMMDS0035: (Non-therapeutic trial) Biologically Focused Therapy of Treatment-Refractory MDS Patients
    - PI: Greenberg Stanford
    - Priority 5

HIGHER RISK MDS

- Failed to respond to Hypomethylating agent
  - HEM0056: Phase Ib/II Safety & Efficacy of Enasidenib in MDS/Myelomonocytic Leukemia without IDH2 Mutation
    - PI: Zhang Stanford University
    - Priority 5

LOWER RISK MDS

- Failure to respond to Erythropoietic stimulating Agent
  - HEMMDS0042: Phase II/III INCB00928 Monotherapy in Subjects w/ Anemia Due To Myelodysplastic Syndromes / Multiple Myeloma
    - PI: Shomali Incyte Corporation
    - Priority 5